<DOC>
	<DOCNO>NCT01034449</DOCNO>
	<brief_summary>This program offer opportunity receive allogeneic transplant try control malignant hematologic absence acceptable conventional donor risk-benefit ratio equivalent would expect transplant conventional donor . An economy mean method could serve alternative 2 unit placental blood transplantation . The current cost disposal unit placental blood bank approximately 22000 € ( Source : Biomedicine Agency , 2007 rate ) . The amplification process control `` EFSAL '' 12000 € . Therefore , buy unit ex-vivo amplification economical . Moreover , availability placental blood infinite , use one unit per patient also save resource valuable certain group patient . In long term , method amplification specific immunocompetent cell ( fraction CD 34 neg cell ) already evaluate laboratory . They allow consider faster recovery , well target , include cell disease transplantation perform .</brief_summary>
	<brief_title>Transplantation Ex-vivo Expanded Cord Blood Stems Cells</brief_title>
	<detailed_description>This multicenter prospective non randomize phase 2 clinical trial . The primary objective define get neutrophil count 500/ml 3 consecutive day day 42 transplantation , association complete partial chimerism T cell ( 10 % 90 % ) . The secondary objective : - feasibility expansion , - tolerance immediate injection graft amplify , - payback platelet count &gt; 20 000/microlitre without transfusion , - Incidence graft loss rejection within 6 month follow transplantation , - incidence acute chronic GVHD , - mortality rate associate transplantation , - incidence relapse hematologic malignancy , - Overall survival , - Disease-free survival 1 year post transplant .</detailed_description>
	<criteria>Age ≥ 18 &lt; 66 year Patient acute myeloid leukemia ( AML ) high risk 1st complete remission : CR1 obtain 2 cycle chemotherapy , unfavorable Cytogenetics FLT3 Duplication , Or acute myeloid leukemia ( AML ) 2nd complete remission , Or acute lymphoblastic leukemia ( ALL ) Highrisk 1st complete remission : Presence translocation ( 9 ; 22 ) , Or acute lymphoblastic leukemia ( ALL ) 2nd complete remission , Or Chronic Myeloid Leukemia ( LCM ) beyond 1st chronic phase Or Myelodysplasia IPSS score 2 Or Hodgkin 's disease sensitive relapse beyond 2nd complete remission . follow type lymphoma : Diffuse large B lymphoma cell relapse refractory two line treatment line autologous hematopoietic stem cell , Mantle cell lymphoma relapse refractory two line treatment line autologous hematopoietic stem cell Others aggressive lymphoma indication allograft select ( Burkitt lymphoma , lymphoblastic lymphoma , intravascular lymphoma , ... ) Lymphoma ( lowgrade follicular lymphoma , marginal zone lymphoma ) histological transformation . Lowgrade lymphoma indication allograft retain Unable receive myeloablative conditioning age ( &gt; 45 year ) and/or existence comorbidities preclude myeloablative conditioning ( status ECOG &gt; / = 2 , DLCO &lt; 50 % , fungal infection proven probable previous 60 day ) / prior treatment total body irradiation dose 2 Gy busulfan dose &gt; 8 mg/kg No contraindication transplant allogeneic nonmyeloablative conditioning , No HLAidentical sibling , Absence unrelated donor national international register 10/10 allelic match 9/10 allelic match tolerated mismatch : HLAC . No unit placental blood available fulfil characteristic compatibility ( HLA compatible least 4/6 allele generic ) richness Provision least 2 unit placental blood , whose compatibility 4/6 , 5/6 6/6 whose richness thawing , &gt; 2 x 107 &lt; 3 4 x 107 nucleated cell per/kg . Patient affiliate social security scheme , Free inform consent sign patient investigator . Age &lt; 18 ≥ 66 year Malignant myeloid lymphoid acute chronic disease without indication allogeneic transplant accord criterion European Bone Marrow Transplantation Group . Able receive myeloablative conditioning age ( &lt; 45 year ) absence co morbidity ( status ECOG &gt; / = 2 , DLCO &lt; 50 % , fungal infection proven probable 60 preceding day ) absence prior treatment total body irradiation dose 2 Gy busulfan dose &gt; 8 mg / kg Contra indication nonmyeloablative conditioning , HLAidentical sibling available Availability unrelated donor national international register 10/10 9/10 HLA matching ( HLAC Mismatch tolerate ) . At least one unit cord blood available characteristic compatibility ( HLA compatible least 4/6 allelic generic ) richness ( thaw &gt; / = 3 4 x 107 nucleated cells/kg recipient , degree compatibility ) Absence least 2 unit placental blood , whose compatibility 4/6 , 5/6 / 6/6 whose richness thaw &gt; 2 x 107 &lt; 4 x 107 nucleated cell per/kg recipient . Women childbearing age use contraception , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>allo graft</keyword>
	<keyword>cord blood</keyword>
	<keyword>expansion</keyword>
	<keyword>reduced-intensity conditioning</keyword>
</DOC>